Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Tolerability and Cognitive Effects of CNV1014802 in Healthy Young vs Elderly Subjects
NCT02359344Phase 1Completed
- Sponsor
- Biogen
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in trigeminal neuralgia (TN) comparing CNV1014802 with Placebo (2 arms). Primary endpoints: Maximum Concentration at 9 days, Area under the concentration curve at 9 days and 5 more. Started Feb 2015; status: completed.
02
Drugs
vixotrigine
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT02359344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359344.